Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports

References

• Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–2350.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang T, Huang Y, et al. Real-world safety and efficacy of consolidation durvalumab after chemoradiotherapy for stage III non-small-cell lung cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys. 2021 112 (5) 1154–1164. .
   PubMed Web of Science ®Google Scholar
• Melillo G, Chand V, Yovine A, et al. Curative-intent treatment with durvalumab in early-stage cancers. Adv Ther. 2021;38:2759–2778.
   PubMed Web of Science ®Google Scholar
• Bryant AK, Yin H, Schipper MJ, et al. Uptake of adjuvant durvalumab after definitive concurrent chemoradiotherapy for stage III nonsmall-cell lung cancer. Am J Clin Oncol. 2022;45:142–145.
   PubMed Web of Science ®Google Scholar
• Käsmann L, Eze C, Taugner J, et al. Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)—a German radiation oncology survey. Transl Lung Cancer Res. 2020;9:288.
   PubMed Web of Science ®Google Scholar
• Faivre-Finn C, Spigel D, Senan S, et al. Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC. Ann Oncol. 2018;29:viii488.
   Web of Science ®Google Scholar
• Stevens SX, Nindra U, Shahnam A, et al. Effect of delayed consolidation durvalumab and timing of treatment on survival outcomes in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT). J clin oncol. 2022 June 01;40(16_suppl):e18809–e18809.
   Web of Science ®Google Scholar
• McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer. JAMA Oncol. 2016;2:46–54.
   PubMed Web of Science ®Google Scholar
• Scorer P, Scott M, Lawson N, et al. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. Diagn Pathol. 2018;13:1–10.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Spira A, Raben D, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020;31:798–806.
   PubMed Web of Science ®Google Scholar
• Jazieh K, Gad M, Saad A, et al. Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab. Transl Lung Cancer Res. 2021;10:3071.
   PubMed Web of Science ®Google Scholar
• Offin M, Shaverdian N, Rimner A, et al. Clinical outcomes, local–regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. Radiother Oncol. 2020;149:205–211.
   PubMed Web of Science ®Google Scholar
• Landman Y, Jacobi O, Kurman N, et al. Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer. Oncoimmunology. 2021;10:1959979.
   PubMed Web of Science ®Google Scholar
• Desilets A, Blanc-Durand F, Lau S, et al. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: a real-world multicentre study. Eur J Cancer. 2021;142:83–91.
   PubMed Web of Science ®Google Scholar
• Kartolo A, Shah H, Hopman W, et al. Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study. Cancer Treat Res Commun. 2021;29:100496.
   PubMedGoogle Scholar
• Rothschild SI, Zippelius A, Eboulet EI, et al. SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non–small-cell lung cancer—a multicenter single-arm phase II trial. J Clin Oncol. 2021;39:2872–2880.
   PubMed Web of Science ®Google Scholar
• Käsmann L, Eze C, Taugner J, et al. Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy. Radiat Oncol. 2020;15:1–14.
   Web of Science ®Google Scholar
• Bradley JD, Nishio M, Okamoto I, et al. PACIFIC-2: phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC. J clin oncol. 2019;37(15_suppl). DOI:10.1200/JCO.2019.37.15_suppl.TPS8573
   Web of Science ®Google Scholar
• Avrillon V, Daniel C, Boisselier P, et al. Nationwide real-life safety and treatment exposure data on durvalumab after concurrent chemoradiotherapy in unresectable stage III, locally advanced, non-small cell lung cancer: analysis of patients enrolled in the french early access program. Lung. 2022;200:95–105.
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. JNCI J Natl Cancer Inst. 2014;106(6). DOI:10.1093/jnci/dju124.
   Web of Science ®Google Scholar
• Bryant AK, Sankar K, Strohbehn GW, et al. Prognostic and predictive value of neutrophil-to-lymphocyte ratio with adjuvant immunotherapy in stage III non-small-cell lung cancer. Lung Cancer. 2022;163:35–41.
   PubMed Web of Science ®Google Scholar
• Ohri N, Halmos B, Bodner WR, et al. Who benefits the most from adjuvant durvalumab after chemoradiotherapy for non-small cell lung cancer? An exploratory analysis. Pract Radiat Oncol. 2021;11:e172–e179.
   PubMed Web of Science ®Google Scholar
• Chu C-H, Chiu T-H, Wang -C-C, et al. Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer. Thorac Cancer. 2020;11:1541–1549.
   PubMed Web of Science ®Google Scholar
• Zhang Y-L, Yuan J-Q, Wang K-F, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985.
   PubMedGoogle Scholar
• Hsu W-H, Yang J-H, Mok T, et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol. 2018;29:i3–i9.
   PubMed Web of Science ®Google Scholar
• Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer—a meta-analysis. J Thorac Oncol. 2017;12:403–407.
   PubMed Web of Science ®Google Scholar
• Oxnard G, Yang J-H, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020;31:507–516.
   PubMed Web of Science ®Google Scholar
• Faivre-Finn C, Vicente D, Kurata T, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC—an update from the PACIFIC trial. J Thorac Oncol. 2021;16:860–867.
   PubMed Web of Science ®Google Scholar
• Aredo JV, Mambetsariev I, Hellyer JA, et al. Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy. J Thorac Oncol. 2021;16:1030–1041.
   PubMed Web of Science ®Google Scholar
• Hellyer JA, Aredo JV, Das M, et al. Role of consolidation durvalumab in patients with EGFR-and HER2-mutant unresectable stage III NSCLC. J Thorac Oncol. 2021;16:868–872.
   PubMed Web of Science ®Google Scholar
• Wang -C-C, Chiu L-C, Ju J-S, et al. Durvalumab as consolidation therapy in post-concurrent chemoradiation (CCRT) in unresectable stage III non-small cell lung cancer patients: a multicenter observational study. Vaccines (Basel). 2021;9:1122.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhang Z, Rinsurongkawong W, et al. Association of driver oncogene variations with outcomes in patients with locally advanced non–small cell lung cancer treated with chemoradiation and consolidative durvalumab. JAMA Network Open. 2022;5:e2215589–e2215589.
   PubMed Web of Science ®Google Scholar
• Offin M, Rizvi H, Tenet M, et al. Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with egfr-mutant lung cancerstmb and efficacy of EGFR-TKI in EGFR-mutant lung cancers. Clin Cancer Res. 2019;25:1063–1069.
   PubMed Web of Science ®Google Scholar
• Sabari J, Leonardi G, Shu C, et al. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol. 2018;29:2085–2091.
   PubMed Web of Science ®Google Scholar
• Schmid S, Garcia M, Cheng S, et al. Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer. Lung Cancer. 2022;166:58–62.
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinomaSTK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant LUAC. Cancer Discov. 2018;8:822–835.
   PubMed Web of Science ®Google Scholar
• Della Corte CM, Sen T, Gay CM, et al. STING pathway expression identifies NSCLC with an immune-responsive phenotype. J Thorac Oncol. 2020;15:777–791.
   PubMed Web of Science ®Google Scholar
• An J, Yan M, Yu N, et al. Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation. Transl Lung Cancer Res. 2021;10:3608.
   PubMed Web of Science ®Google Scholar
• Hayes JD, Dinkova-Kostova AT. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci. 2014;39:199–218.
   PubMed Web of Science ®Google Scholar
• Best SA, Sutherland KD. “Keaping” a lid on lung cancer: the Keap1-Nrf2 pathway. Cell Cycle. 2018;17:1696–1707.
   PubMed Web of Science ®Google Scholar
• Binkley MS, Jeon Y-J, Nesselbush M, et al. KEAP1/NFE2L2 mutations predict lung cancer radiation resistance that can be targeted by glutaminase inhibitionKEAP1/NFE2L2 mutations predict lung cancer radio resistance. Cancer Discov. 2020;10:1826–1841.
   PubMed Web of Science ®Google Scholar
• Shaverdian N, Offin M, Shepherd AF, et al. The impact of durvalumab on local-regional control in stage III NSCLCs treated with chemoradiation and on KEAP1-NFE2L2-mutant tumors. J Thorac Oncol. 2021;16:1392–1402.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387:1837–1846.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265.
   PubMed Web of Science ®Google Scholar
• Marinelli D, Mazzotta M, Scalera S, et al. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Ann Oncol. 2020;31:1746–1754.
   PubMed Web of Science ®Google Scholar
• Gibney GT, Weiner LM, Atkins MB. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 2016;17:e542–e551.
   PubMed Web of Science ®Google Scholar
• Genova C, Dellepiane C, Carrega P, et al. Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade. Front Immunol. 2021;12:799455.
   PubMed Web of Science ®Google Scholar
• You W, Shang B, Sun J, et al. Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: a paradigm shift towards immunome evaluation. Oncol Rep. 2020;44:424–437.
   PubMed Web of Science ®Google Scholar
• Sheth S, Gao C, Mueller N, et al. Durvalumab activity in previously treated patients who stopped durvalumab without disease progression. Ann Oncol. 2019;30:v475–v476.
   Web of Science ®Google Scholar
• Higgs BW, Morehouse CA, Streicher K, et al. Interferon gamma messenger RNA Signature in tumor biopsies predicts outcomes in patients with non–small cell lung carcinoma or urothelial cancer treated with durvalumab. Clin Cancer Res. 2018;24:3857–3866.
   PubMed Web of Science ®Google Scholar
• Cheng L, Creasy T, Pilataxi F, et al. Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma. Cancer Immunol Immunother. 2022;71:1167–1181.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chen L. Classification of advanced human cancers based on tumor immunity in the microenvironment (TIME) for cancer immunotherapy. JAMA Oncol. 2016;2:1403–1404.
   PubMed Web of Science ®Google Scholar
• Shirasawa M, Yoshida T, Imabayashi T, et al. Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer. Eur J Cancer. 2022;162:1–10.
   PubMed Web of Science ®Google Scholar
• Gennen K, Käsmann L, Taugner J, et al. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiat Oncol. 2020;15:5.
   PubMed Web of Science ®Google Scholar
• Gavrilov S, Zhudenkov K, Helmlinger G, et al. Longitudinal tumor size and neutrophil‐to‐lymphocyte ratio are prognostic biomarkers for overall survival in patients with advanced non‐small cell lung cancer treated with durvalumab. CPT Pharmacomet Syst Pharmacol. 2021;10:67–74.
   PubMedGoogle Scholar
• Jazieh K, Khorrami M, Saad A, et al. Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab. J Immunother Cancer. 2022;10(3):e003778.
   PubMed Web of Science ®Google Scholar
• Angell HK, Bruni D, Barrett JC, et al. The immunoscore: colon cancer and beyond. Clin Cancer Res. 2020;26:332–339.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964.
   PubMed Web of Science ®Google Scholar
• Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours. J Pathol. 2014;232:199–209.
   PubMed Web of Science ®Google Scholar
• Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248–262.
   PubMed Web of Science ®Google Scholar
• Martinez-Marti A, Majem M, Barlesi F, et al. LBA42 COAST: an open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC. Ann Oncol. 2021;32:S1320.
   Web of Science ®Google Scholar
• Herbst RS, Majem M, Barlesi F, et al. COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage iii non–small-cell lung cancer. J Clin Oncol. 2022;40(29):3383–3393.
   PubMed Web of Science ®Google Scholar
• Antonioli L, Yegutkin GG, Pacher P, et al. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer. 2016;2:95–109.
   PubMed Web of Science ®Google Scholar
• André P, Denis C, Soulas C, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731–1743.
   PubMed Web of Science ®Google Scholar